Literature DB >> 18070219

Clinical uses of interferons.

Robert M Friedman1.   

Abstract

Interferons were first described by Isaacs & Lindenmann working at the National Institute for Medical Research, Mill Hill in 1957. Thus, the fiftieth year of their discovery is being celebrated this year at Oxford in a meeting of the International Society for Interferon and Cytokine Research. This then is an appropriate time to review the clinical applications of the interferons. To accomplish this coherently it is necessary also to review briefly what led to the discovery of interferons, why their clinical applications were so slow in coming, and the impact of interferon research on the biomedical sciences.

Mesh:

Substances:

Year:  2007        PMID: 18070219      PMCID: PMC2253698          DOI: 10.1111/j.1365-2125.2007.03055.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  36 in total

Review 1.  Role of interferons and other cytokines in the regulation of the immune response.

Authors:  F Belardelli
Journal:  APMIS       Date:  1995-03       Impact factor: 3.205

2.  Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma.

Authors:  T C Merigan; K Sikora; J H Breeden; R Levy; S A Rosenberg
Journal:  N Engl J Med       Date:  1978-12-28       Impact factor: 91.245

3.  Partial purification of human leukocyte interferon on a large scale.

Authors:  K Cantell; S Hirvonen; V Koistinen
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

Review 4.  Interferon-gamma: biology and role in pathogenesis.

Authors:  A Billiau
Journal:  Adv Immunol       Date:  1996       Impact factor: 3.543

5.  Human leukocyte interferon in the treatment of varicella in children with cancer: a preliminary controlled trial.

Authors:  A M Arvin; S Feldman; T C Merigan
Journal:  Antimicrob Agents Chemother       Date:  1978-04       Impact factor: 5.191

6.  Human leukocyte (alpha) interferon in metastatic malignant melanoma: the American Cancer Society phase II trial.

Authors:  S E Krown; M W Burk; J M Kirkwood; D Kerr; D L Morton; H F Oettgen
Journal:  Cancer Treat Rep       Date:  1984-05

7.  Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia.

Authors:  M Talpaz; K B McCredie; G M Mavligit; J U Gutterman
Journal:  Blood       Date:  1983-09       Impact factor: 22.113

8.  Renal cell carcinoma: antitumor effects of leukocyte interferon.

Authors:  J R Quesada; D A Swanson; A Trindade; J U Gutterman
Journal:  Cancer Res       Date:  1983-02       Impact factor: 12.701

9.  [Intralesional treatment of classical Kaposi sarcoma with interferon-alpha].

Authors:  A Hauschild; C Petres-Dunsche
Journal:  Hautarzt       Date:  1992-12       Impact factor: 0.751

10.  Intrathecal interferon in multiple sclerosis.

Authors:  L Jacobs; J O'Malley; A Freeman; J Murawski; R Ekes
Journal:  Arch Neurol       Date:  1982-10
View more
  30 in total

Review 1.  Into the eye of the cytokine storm.

Authors:  Jennifer R Tisoncik; Marcus J Korth; Cameron P Simmons; Jeremy Farrar; Thomas R Martin; Michael G Katze
Journal:  Microbiol Mol Biol Rev       Date:  2012-03       Impact factor: 11.056

2.  Sensitivity: real (interferons, odorants) and imagined (homeopathy).

Authors:  J M Ritter
Journal:  Br J Clin Pharmacol       Date:  2008-02       Impact factor: 4.335

3.  Looking back: editors' pick of 2008.

Authors:  Y K Loke; A Somogyi; L D Lewis; M Schachter; A F Cohen; J M Ritter
Journal:  Br J Clin Pharmacol       Date:  2009-01       Impact factor: 4.335

4.  FoxO3a nuclear localization and its association with β-catenin and Smads in IFN-α-treated hepatocellular carcinoma cell lines.

Authors:  María Paula Ceballos; Juan Pablo Parody; Ariel Darío Quiroga; María Laura Casella; Daniel Eleazar Francés; María Cecilia Larocca; Cristina Ester Carnovale; María de Luján Alvarez; María Cristina Carrillo
Journal:  J Interferon Cytokine Res       Date:  2014-06-20       Impact factor: 2.607

5.  Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43.

Authors:  Magdalena Sarasin-Filipowicz; Xueya Wang; Ming Yan; Francois H T Duong; Valeria Poli; Douglas J Hilton; Dong-Er Zhang; Markus H Heim
Journal:  Mol Cell Biol       Date:  2009-06-29       Impact factor: 4.272

Review 6.  Innate immune evasion strategies of influenza viruses.

Authors:  Benjamin G Hale; Randy A Albrecht; Adolfo García-Sastre
Journal:  Future Microbiol       Date:  2010-01       Impact factor: 3.165

Review 7.  Too much of a good thing: Detrimental effects of interferon.

Authors:  Nancy C Reich
Journal:  Semin Immunol       Date:  2019-06       Impact factor: 11.130

8.  Activation of protein kinase C{eta} by type I interferons.

Authors:  Amanda J Redig; Antonella Sassano; Beata Majchrzak-Kita; Efstratios Katsoulidis; Hui Liu; Jessica K Altman; Eleanor N Fish; Amittha Wickrema; Leonidas C Platanias
Journal:  J Biol Chem       Date:  2009-02-11       Impact factor: 5.157

9.  5'PPP-RNA induced RIG-I activation inhibits drug-resistant avian H5N1 as well as 1918 and 2009 pandemic influenza virus replication.

Authors:  Priya Ranjan; Lakshmi Jayashankar; Varough Deyde; Hui Zeng; William G Davis; Melissa B Pearce; John B Bowzard; Mary A Hoelscher; Victoria Jeisy-Scott; Mayim E Wiens; Shivaprakash Gangappa; Larisa Gubareva; Adolfo García-Sastre; Jacqueline M Katz; Terrence M Tumpey; Takashi Fujita; Suryaprakash Sambhara
Journal:  Virol J       Date:  2010-05-21       Impact factor: 4.099

10.  In silico analysis and experimental validation of azelastine hydrochloride (N4) targeting sodium taurocholate co-transporting polypeptide (NTCP) in HBV therapy.

Authors:  L-L Fu; J Liu; Y Chen; F-T Wang; X Wen; H-Q Liu; M-Y Wang; L Ouyang; J Huang; J-K Bao; Y-Q Wei
Journal:  Cell Prolif       Date:  2014-06-26       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.